Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum.
Wang J, Zhang CJ, Chia WN, Loh CC, Li Z, Lee YM, He Y, Yuan LX, Lim TK, Liu M, Liew CX, Lee YQ, Zhang J, Lu N, Lim CT, Hua ZC, Liu B, Shen HM, Tan KS, Lin Q. · 2015
Read Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. by Wang J, Zhang CJ, Chia WN, Loh CC, Li Z, Lee YM, He Y, Yuan LX, Lim TK, Liu M, Liew CX, Lee YQ, Zhang J, Lu N, Lim CT, Hua ZC, Liu B, Shen HM, Tan KS, Lin Q. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4703832.txt.
Introduction
Jigang Wang, Chong-Jing Zhang, Wan Ni Chia, and a large team probed how the malaria drug artemisinin works, in Nature Communications in 2015. Artemisinin and its relatives are the strongest anti-malaria drugs known, yet their killing mechanism stayed partly mysterious for decades. The team attached a chemical tag to the drug, fished out everything it bound inside the malaria parasite Plasmodium falciparum, and identified the catch by protein analysis.
The drug bound 124 parasite proteins, many of them essential, a spread so wide it wrecks the parasite's chemistry wholesale. A fluorescent version of the tagged drug settled a second dispute: haem, not free iron, mainly switches the drug on. That haem comes from the parasite's own production early in its cycle and from digested blood later. The results support one unified model of the drug's action and its deadly aim at this parasite.
Catalog record
| CREATOR | Wang J, Zhang CJ, Chia WN, Loh CC, Li Z, Lee YM, He Y, Yuan LX, Lim TK, Liu M, Liew CX, Lee YQ, Zhang J, Lu N, Lim CT, Hua ZC, Liu B, Shen HM, Tan KS, Lin Q. |
|---|---|
| YEAR | 2015 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 69 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum By Jigang Wang, Chong-Jing Zhang, Wan Ni Chia, Cheryl C Y Loh, Zhengjun Li, Yew Mun Lee, Yingke He, Li-Xia Yuan, Teck Kwang Lim, Min Liu, Chin Xia Liew, Yan Quan Lee Published in: Nature Communications DOI: 10.1038/ncomms10111 ABSTRACT Abstract The mechanism of action of artemisinin and its derivatives, the most potent of the anti-malarial drugs, is not completely understood. Here we present an unbiased chemical proteomics analysis to directly explore this mechanism in Plasmodium falciparum. We use an alkyne-tagged artemisinin analogue coupled with biotin to identify 124 artemisinin covalent binding protein targets, many of which are involved in the essential biological processes of the parasite. Such a broad targeting spectrum disrupts the biochemical landscape of the parasite and causes its death. Furthermore, using alkyne-tagged artemisinin coupled with a fluorescent dye to monitor protein binding, we show that haem, rather than free ferrous iron, is predominantly responsible for artemisinin activation. The haem derives primarily from the parasite's haem biosynthesis pathway at the early ring stage and from haemoglobin digestion at the latter stages. Our results support a unifying model to explain the action and specificity of artemisinin in parasite killing. Plasmodium falciparum, the most pathogenic human malaria parasite, infects millions of human beings and poses a serious public health threat. Currently, the most potent anti-malarial drugs are artemisinin and its derivatives1,2. Artemisinin is a sesquiterpene lactone with an endoperoxide bridge3. The hallmark of artemisinin activation is the generation of highly reactive carbon-centred radicals via endoperoxide cleavage4,5,6. Even after several decades of intensive studies on the mechanism of action of artemisinin7,8, two critical yet unresolved long-standing questions remain. The first concerns the origin of iron sources required for artemisinin activation. Both free ferrous iron9,10 and haem11 have been proposed to be the predominant iron sources for its activation, but the results of relevant research are controversial. The second question concerns the exact targets of activated artemisinin. Although several proteins have been reported to be the drug targets8,9,12, none of them could satisfactorily account for the quick and highly potent killing effect of artemisinin. It is possible that activated artemisinin might have many other direct targets due to the promiscuous nature of the radicals3,6,8. To address these questions, it is critical to develop an approach to directly study the artemisinin–protein interaction. Here we have developed an unbiased chemical proteomics approach and systematically identified 124 artemisinin covalent binding targets. Many of the identified targets are involved in essential biological processes. We have validated several artemisinin–protein interactions through in vitro binding assays and orthogonal confirmatory experiments. Importantly, targeted enzyme activity was impaired on artemisinin binding in the tested proteins. Thus, our data support the hypothesis that activated artemisinin may kill the malaria parasite through a promiscuous targeting mechanism. In addition, we use in vitro binding analyses to show that haem, rather than free ferrous iron, is predominantly responsible for artemisinin activation. These findings are also supported by an ex vivo cancer cell model. The source of haem required for artemisinin is derived from the parasite's haem biosynthesis pathway at the early ring stage and from haemoglobin digestion at latter stages. Thus, the ‘blood-eating' nature of the parasite with the release of extremely high levels of haem confers the high efficacy of artemisinin against the parasites, with minimum side effects towards healthy red blood cells (RBCs). Our results support a unifying model to explain the action and specificity of artemisinin in parasite killing and could facilitate the development of better strategies to treat malaria in times of emerging artemisinin resistance. RESULTS Synthesis of an artemisinin-based activity probe (AP1) To profile and identify the targets of artemisinin, AP1, a chemically engineered artemisinin with a clickable alkyne tag attached13,14,15,16,17,18,19,20,21,22, was designed and synthesized (Fig. 1a, probe synthesis scheme is shown in Supplementary Fig. 1). The alkyne tag can be further appended with a fluorescent dye or a biotin moiety through click chemistry, allowing the AP1 covalent binding targets to be visualized on SDS–polyacrylamide gel electrophoresis (PAGE) or affinity purified for mass spectrometric identification (Fig. 1b). [Figure: The chemical proteomics approach to study artemisinin's mechanism of action.(a) Chemical structures of artemisinin (Art), artesunate (Arts) and the alkyne-tagged-clickable probe (AP1). (b) General workflow of the chemical proteomics approach. Fluorescence labelling was used to study the activation mechanism of artemisinin, while biotin pull-downs coupled with LC–MS/MS were used to identify protein targets of artemisinin. (c) The killing effect of AP1 is comparable to that of artemisinin and artesunate on P. falciparum 3D7. (d) In situ parasite labelling with AP1. The labelling was dose dependent and specific to parasite proteins. Healthy RBC cytosolic proteins were not labelled. (e) The AP1 in situ parasite labelling was artemisinin specific as the excess Arts can largely compete with AP1-target labelling. (f) Free-radical scavenger (Tiron, 1 mM; Trolox, 400 μM; TEMPO, 1 mM) co-treatment reduces the level of parasite protein alkylation by AP1. Fluo, fluorescence scanning; Coo, Coomassie staining. Error bars represent s.d. in three independent replicates in c. Full-gel images for panels d and f are shown in Supplementary Fig. 13.] Fluorescence labelling of artemisinin targets in parasites First, we tested the anti-malarial activity of AP1 on two different parasite strains, the laboratory line P. falciparum 3D7 and the field isolate ARS270. AP1 was as potent as the unmodified artemisinin, suggesting that the addition of the clickable alkyne tag does not interfere with drug activity (Fig. 1c and Supplementary Fig. 2). Crude protein extracts were prepared from AP1-treated live parasites, clicked with a fluorescent dye and resolved by SDS–PAGE. Only AP1 covalent binding targets can be labelled and visualized with fluorescence scanning. Many parasite proteins were fluorescently labelled in an AP1 dose-dependent manner, whereas AP1 failed to react with proteins from healthy RBCs under the same conditions (Fig. 1d). This indicates that AP1 can only be activated inside the parasite but not in the uninfected RBC. We further examined the AP1 labelling of the infected RBCs. The results showed that some of the host cell proteins were also labelled when the RBCs were infected with parasites, although the labelling level was low (Supplementary Fig. 3). This might have been due to the release of parasite-activated drug into the cytosol of infected RBCs. However, this will not cause significant side effects, as the majority of the activated drug is confined within the infected RBCs, as evidenced by the observation that the drug failed to label the uninfected RBCs. Our results ascertained that artemisinin has high specificity towards the malaria parasite and infected RBCs, with minimum side effects towards healthy RBCs. Moreover, AP1 labelling was markedly decreased with preincubation of excess artesunate (a water-soluble artemisinin analogue) (Fig. 1e), suggesting that AP1 binds to the same protein targets as artemisinin. In addition, co-incubation with free-radical scavengers (Tiron, Trolox and TEMPO) also reduced the binding activity of AP1 (Fig. 1f). Collectively, these results indicate that the engineered AP1 is pharmacologically similar to artemisinin. The fluorescence intensity of AP1-labelled proteins on SDS–PAGE serves as a convenient read-out for AP1 binding activity. Identification of artemisinin targets Next, we went on to identify the covalent binding targets of AP1. To do so, live parasites (unsynchronized) were incubated for 4 h with 500 nM